KNSA实时信号 | 通过Getagraph.com最大化利润

出售 116357 min ago

@ $19.84

发出时间: 14 Feb 2024 @ 04:47

回报率: 1.21%

上一信号: Feb 13 - 02:31

上一信号: 购买

回报率: -4.34 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	396 335
平均成交量	387 666
市值	1.42B
EPS	$0 ( 2024-04-23 )
下一个收益日期	( $-0.140 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	154.46
ATR14	$0.0120 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-26	Ragosa Mark	Buy	991	Class A Common Share
2024-04-26	Ragosa Mark	Sell	509	Class A Common Share
2024-04-26	Ragosa Mark	Buy	991	Restricted Share Unit
2024-04-04	Patel Sanj K	Buy	129 750	Share Option
2024-04-08	Patel Sanj K	Buy	9 992	Class A Common Share

INSIDER POWER
24.48
Last 100 transactions
Buy: 574 001 \| Sell: 364 351

音量相关性

長: 0.23 (neutral)

短: 0.93 (very strong)

Signal:(66.151) Expect same movement, but be aware

Kiniksa Pharmaceuticals 相关性

10 最正相关
CSSEP	0.955
EVLO	0.953
GOOD	0.952
SIRI	0.951
ORPH	0.95
ALXO	0.95
NAKD	0.95
AYTU	0.949
LSXMA	0.948
LSXMK	0.948

10 最负相关
CPAQ	-0.966
HERA	-0.966
TBSA	-0.965
AGGR	-0.965
LGAC	-0.965
ACQR	-0.964
APXI	-0.964
KAII	-0.964
FICV	-0.963
HERAU	-0.963

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kiniksa Pharmaceuticals 相关性 - 货币/商品

-0.42
( neutral )

-0.37
( neutral )

0.00
( neutral )

-0.47
( neutral )

0.40
( neutral )

0.48
( neutral )

Kiniksa Pharmaceuticals 财务报表

Annual	2023
营收:	$270.26M
毛利润:	$179.22M (66.31 %)
EPS:	$0.200

FY	2023
营收:	$270.26M
毛利润:	$179.22M (66.31 %)
EPS:	$0.200

FY	2022
营收:	$220.18M
毛利润:	$173.21M (78.67 %)
EPS:	$2.64

FY	2021
营收:	$38.54M
毛利润:	$29.44M (76.39 %)
EPS:	$-2.30

Financial Reports:

No articles found.

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

实时更新： Kiniksa Pharmaceuticals [KNSA]

Upcoming Earnings Alert